{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:21Z","timestamp":1792512141530,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020853","name":"Spondyloarthritis Research and Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102142","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:15:43Z","timestamp":1775247343000},"page":"102142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Malignancy and rheumatic diseases"],"prefix":"10.1016","volume":"40","author":[{"given":"Savannah","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-5797","authenticated-orcid":false,"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102142_bib1","first-page":"10","volume":"75","author":"Siegel","year":"2025","journal-title":"Cancer Statistics"},{"key":"10.1016\/j.berh.2026.102142_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib3","series-title":"Seminars in arthritis and rheumatism","article-title":"Cancer risk in Sj\u00f6gren\u2019s disease: a longitudinal cohort study on incidence, predictors, and mortality impact","author":"Rusinovich-Lovgach","year":"2025"},{"key":"10.1016\/j.berh.2026.102142_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren's syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102142_bib5","article-title":"Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2026.102142_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.berh.2026.102142_bib7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/art.42961","article-title":"The risk of lung cancer in rheumatoid arthritis and rheumatoid arthritis\u2013associated interstitial lung disease","volume":"76","author":"Brooks","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3899\/jrheum.2024-0724","article-title":"Cancer incidence and outcome for patients with Rheumatoid Arthritis: a long-term population study in Western Australia","volume":"52","author":"Nossent","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2013-204993","article-title":"Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ard.2025.01.026","article-title":"Risk of HPV-associated precancer and cancer in women with systemic lupus erythematosus","volume":"84","author":"Siddiqi","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib12","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/ajt.15495","article-title":"Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer","volume":"19","author":"Engels","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.berh.2026.102142_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.berh.2026.102142_bib14","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/j.1600-6143.2008.02368.x","article-title":"Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients","volume":"8","author":"Martinez","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.berh.2026.102142_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fonc.2019.00160","article-title":"Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients","volume":"9","author":"Cangemi","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.berh.2026.102142_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2025.105944","article-title":"French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases","author":"Avouac","year":"2025","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2026.102142_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102142_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Regional Health\u2013Europe"},{"key":"10.1016\/j.berh.2026.102142_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001241","article-title":"Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002\u20132017","volume":"6","author":"Singh","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2026.102142_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001698","article-title":"Lymphoma complicating rheumatoid arthritis: results from a French case\u2013control study","volume":"7","author":"Kedra","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2026.102142_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2023.10.006","article-title":"Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study","volume":"19","author":"Cho","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.berh.2026.102142_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2021.5680","article-title":"Immune-mediated diseases associated with cancer risks","volume":"8","author":"He","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.berh.2026.102142_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11926-016-0563-2","article-title":"The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis","volume":"18","author":"Sparks","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2026.102142_bib24","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"Bmj"},{"key":"10.1016\/j.berh.2026.102142_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/annrheumdis-2019-216756","article-title":"Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors","volume":"79","author":"Wadstr\u00f6m","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib26","first-page":"551","article-title":"Low incidence of colorectal cancer in patients with rheumatoid arthritis","volume":"14","author":"Kauppi","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2026.102142_bib28","first-page":"1","article-title":"Detection of lung abnormalities in smokers with rheumatoid arthritis screened for lung cancer with low\u2010dose chest computed tomography imaging in routine clinical care: results from a large multi\u2010hospital system","volume":"0","author":"McDermott","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102142_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11739-015-1270-0","article-title":"Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience","volume":"11","author":"Fanto","year":"2016","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.berh.2026.102142_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18553\/jmcp.2018.17421","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using US administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J Manag Care Specialty Pharm"},{"key":"10.1016\/j.berh.2026.102142_bib32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib33","series-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J","first-page":"241","volume":"vol. 22","author":"Hagberg","year":"2016"},{"key":"10.1016\/j.berh.2026.102142_bib34","series-title":"Seminars in arthritis and rheumatism","first-page":"144","article-title":"Malignancy in psoriatic disease: results from prospective longitudinal cohorts","author":"Polachek","year":"2021"},{"key":"10.1016\/j.berh.2026.102142_bib35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3892\/ol.2017.6368","article-title":"Ankylosing spondylitis and the risk of cancer","volume":"14","author":"Chang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.berh.2026.102142_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/ard.2002.004721","article-title":"Cancer incidence among patients with ankylosing spondylitis in Sweden 1965\u201395: a population based cohort study","volume":"62","author":"Feltelius","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib37","series-title":"Seminars in arthritis and rheumatism","first-page":"626","article-title":"Malignancy development risk in psoriatic arthritis patients undergoing treatment: a systematic review and meta-analysis","author":"Luo","year":"2019"},{"key":"10.1016\/j.berh.2026.102142_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2230.1991.tb00314.x","article-title":"Psoriasis therapy and the risk of skin cancers","volume":"16","author":"Mali\u2010Gerrits","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102142_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jdv.12742","article-title":"Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink","volume":"29","author":"Edson\u2010Heredia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102142_bib40","first-page":"keae294","article-title":"Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies","author":"Yu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.rdc.2020.04.001","article-title":"Risk of malignancy in spondyloarthritis: a systematic review","volume":"46","author":"Karmacharya","year":"2020","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.berh.2026.102142_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s41927-022-00275-x","article-title":"Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database","volume":"6","author":"Bittar","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib43","first-page":"3388","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood,J Am Soc Hematol"},{"key":"10.1016\/j.berh.2026.102142_bib44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.rdc.2020.05.004","article-title":"Sj\u00f6gren syndrome and cancer","volume":"46","author":"Igoe","year":"2020","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.berh.2026.102142_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/03009742.2018.1523456","article-title":"Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sj\u00f6gren\u2019s syndrome","volume":"48","author":"Vasaitis","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4048\/jbc.2011.14.4.337","article-title":"Clinically positive axillary lymphadenopathy May lead to false diagnosis of overstaged breast cancer in patients with Sj\u00f6gren's Syndrome: a case report","volume":"14","author":"Cipe","year":"2011","journal-title":"J Breast Canc"},{"key":"10.1016\/j.berh.2026.102142_bib48","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00296-019-04433-2","article-title":"Incidence of cancer in a cohort of patients with primary Sj\u00f6gren syndrome in Argentina","volume":"39","author":"Brom","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2026.102142_bib49","first-page":"946","article-title":"The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sj\u00f6gren\u2019s syndrome: a nationwide retrospective case-control study in Taiwan","volume":"37","author":"Tseng","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102142_bib51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.berh.2026.102142_bib52","first-page":"1","article-title":"Cancer risk in patients with systemic lupus erythematosus: a population-based cohort study in the Republic of Korea 2004\u20132021","author":"Choi","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-018-1760-3","article-title":"The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102142_bib54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3899\/jrheum.170652","article-title":"Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus","volume":"45","author":"Bernatsky","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib55","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/00016489.2013.800228","article-title":"Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus","volume":"133","author":"Chang","year":"2013","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.berh.2026.102142_bib56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102142_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.rdc.2020.05.005","article-title":"Cancer and systemic lupus erythematosus","volume":"46","author":"Ladouceur","year":"2020","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.berh.2026.102142_bib58","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3899\/jrheum.171459","article-title":"Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus","volume":"45","author":"Keeling","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib59","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/0961203315575587","article-title":"What investigations are needed to optimally monitor for malignancies in SLE?","volume":"24","author":"Tessier-Cloutier","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2026.102142_bib61","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/acr.25595","article-title":"Cancer risk in patients with systemic sclerosis: a nationwide cohort study in South Korea 2004\u20102021","volume":"77","author":"Na","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102142_bib62","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta\u2010analysis of population\u2010based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102142_bib63","first-page":"551","volume":"vol. 46","author":"Weeding","year":"2020"},{"key":"10.1016\/j.berh.2026.102142_bib64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/03009742.2011.618145","article-title":"Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan","volume":"41","author":"Kuo","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib65","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102142_bib66","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer\u2010associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.berh.2026.102142_bib68","first-page":"9","article-title":"Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark","volume":"6","author":"Chow","year":"1995","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.berh.2026.102142_bib69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Moghadam-Kia","year":"2020","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.berh.2026.102142_bib70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.berh.2026.102142_bib71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib72","series-title":"Seminars in arthritis and rheumatism","first-page":"301","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","author":"Dobloug","year":"2015"},{"key":"10.1016\/j.berh.2026.102142_bib73","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102142_bib75","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib76","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer\u2010associated dermatomyositis have antibodies to nuclear matrix protein NXP\u20102 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102142_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101698","article-title":"Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients","volume":"75","author":"Shao","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.berh.2026.102142_bib78","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102142_bib79","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.berh.2026.102142_bib80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis\u2014common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102142_bib81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102142_bib82","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib83","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jbspin.2017.08.003","article-title":"Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs","volume":"85","author":"Atzeni","year":"2018","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2026.102142_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2013.834961","article-title":"Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis","volume":"43","author":"Van der Heijde","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib85","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short-and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib86","first-page":"keaf556","article-title":"Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry","author":"Molina-Collada","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib87","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.berh.2026.102142_bib88","series-title":"Seminars in arthritis and rheumatism","first-page":"71","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","author":"Carmona","year":"2011"},{"key":"10.1016\/j.berh.2026.102142_bib89","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib90","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib91","series-title":"Seminars in arthritis and rheumatism","first-page":"222","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","author":"Kim","year":"2019"},{"key":"10.1016\/j.berh.2026.102142_bib92","series-title":"Seminars in arthritis and rheumatism","first-page":"930","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","author":"Xie","year":"2020"},{"key":"10.1016\/j.berh.2026.102142_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70193","article-title":"Comparative safety of biologic and targeted\u2010synthetic DMARDs in patients with rheumatoid arthritis: a multi\u2010database real\u2010world cohort Study","volume":"34","author":"Jin","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.berh.2026.102142_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.berh.2026.102142_bib95","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib96","series-title":"Seminars in arthritis and rheumatism","first-page":"489","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","author":"Solomon","year":"2014"},{"key":"10.1016\/j.berh.2026.102142_bib97","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab\u2010treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow\u2010up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102142_bib98","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?\u2014Insights from an international population\u2010based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102142_bib99","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jamadermatol.2025.3928","article-title":"Comparative cancer risk in patients with psoriasis treated with Adalimumab, secukinumab, or ustekinumab","volume":"161","author":"Schwarz","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102142_bib100","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2025.2056","article-title":"Ixekizumab and malignant neoplasms: a pooled analysis of data from 25 randomized clinical trials","volume":"161","author":"Merola","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102142_bib101","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102142_bib102","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib103","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Solitano","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.berh.2026.102142_bib104","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2026.102142_bib105","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s10067-020-05318-7","article-title":"Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy","volume":"39","author":"Pundole","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib106","series-title":"Seminars in arthritis and rheumatism","first-page":"30","article-title":"Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: a register-based cohort study from Denmark","author":"Cordtz","year":"2020"},{"key":"10.1016\/j.berh.2026.102142_bib107","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/1097-0142(197606)37:6<2703::AID-CNCR2820370620>3.0.CO;2-H","article-title":"Adjuvant methotrexate in the radio\u2010therapeutic management of advanced tumors of the head and neck","volume":"37","author":"Lustig","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.berh.2026.102142_bib108","first-page":"643","article-title":"Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib109","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/rheumatology\/kez475","article-title":"A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy","volume":"59","author":"Xie","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102142_bib110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-025-01738-4","article-title":"Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis","volume":"25","author":"Isufi","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.berh.2026.102142_bib111","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","article-title":"Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta-analysis","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2026.102142_bib112","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/acr.24784","article-title":"Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta\u2010analysis","volume":"75","author":"Wetzman","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102142_bib113","series-title":"Arthritis & rheumatology","first-page":"3328","article-title":"Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors","author":"Suarez-Almazor","year":"2023"},{"key":"10.1016\/j.berh.2026.102142_bib114","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2665-9913(24)00379-5","article-title":"Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study","volume":"7","author":"Ruiz","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib115","first-page":"388","article-title":"EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib116","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.05.091","article-title":"OP0068 Survival in patients with rheumatoid arthritis and early-stage melanoma treated with methotrexate or tumor necrosis factor alpha inhibitors","volume":"84","author":"Suarez-Almazor","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102142_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102142_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-025-01200-0","article-title":"Treatment of persons with rheumatoid arthritis with a history of cancer","volume":"27","author":"Shasti-Nazem","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2026.102142_bib119","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2026.102142_bib120","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00296-024-05571-y","article-title":"Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease","volume":"44","author":"Farina","year":"2024","journal-title":"Rheumatol Int"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:10Z","timestamp":1781509570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000276"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102142","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy and rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102142"}}